Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 597Stomach Neoplasms 72Neoplasm Metastasis 56Neoplasms 35HER2-positive Breast Cancer 30Breast Neoplasms, Male 30Colorectal Neoplasms 28Brain Neoplasms 23Carcinoma, Non-Small-Cell Lung 21Inflammatory Breast Neoplasms 20Esophageal Neoplasms 20Pancreatic Neoplasms 13Triple Negative Breast Neoplasms 12Lung Neoplasms 11Endometrial Neoplasms 11Ovarian Neoplasms 10Colonic Neoplasms 10Urinary Bladder Neoplasms 9Rectal Neoplasms 9Prostatic Neoplasms 9Adenocarcinoma 8Salivary Gland Neoplasms 7Gallbladder Neoplasms 7Breast Diseases 7Biliary Tract Neoplasms 7Adenocarcinoma Of Esophagus 7Uterine Cervical Neoplasms 6Squamous Cell Carcinoma of Head and Neck 6Sarcoma 6Pathologic Complete Response 6

Interventions

spartalizumab 1sintilimab 1pyrotinib 1pertuzumab 1palbociclib 1Trastuzumab 1Taxes 1Letrozole 1Everolimus 1Capecitabine 1Albumin-Bound Paclitaxel 1Ado-Trastuzumab Emtansine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × HER2+ Breast Cancer × Trastuzumab × Clear all
NCT05429684 2022-06-23

Precise Therapy for Refractory HER2 Positive Advanced Breast Cancer

First Affiliated Hospital Xi'an Jiaotong University

Phase 3 Unknown
120 enrolled
Breast

HER2+ Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡